V2R Antagonist Combinations for Clear Cell Renal Carcinoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic methods are inadequate for effectively treating clear cell renal cell carcinoma (RCC), particularly in suppressing tumor growth and proliferation, as V2R antagonists have shown mixed results in RCC cell lines and human tumors.
Innovation Solution
The use of V2R antagonists such as OPC31260 and OPC41061, administered effectively to subjects, which inhibit V2R signaling, reducing cell proliferation, angiogenesis, and tumor growth in clear cell RCC by inducing cell cycle arrest and apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If V2R antagonists are used to treat clear cell renal cell carcinoma, then tumor growth suppression is improved, but treatment reliability is worsened due to mixed results in RCC cell lines and human tumors
Solution Approach 1:
The patent combines multiple V2R antagonists (OPC31260 and OPC41061) in specific dosage ratios to change the treatment parameters, achieving synergistic effects that improve both tumor growth suppression and treatment consistency compared to single-agent therapy
Solution Approach 2:
The invention uses a composite approach by combining two different V2R antagonist compounds (OPC31260 and OPC41061) into a single treatment regimen, where the composite effect of both agents addresses the reliability issue while maintaining improved tumor growth suppression
2Productivity
If higher doses of V2R antagonists are administered to improve tumor growth suppression, then therapeutic efficacy is improved, but potential side effects worsen
Solution Approach 1:
The patent uses sub-maximal doses of each individual V2R antagonist (OPC31260 and OPC41061) in combination, where the partial action of each agent at lower doses achieves the same therapeutic efficacy as higher single-agent doses while reducing side effects through synergistic interaction
Data Source
AI summary
The present disclosure is directed, among other things, to the surprising and unexpected efficacy provided by select V2R antagonists in significantly reducing the cell proliferation levels of clear cell renal cell carcinoma. Thus, the present disclosure provides methods, uses, and medicaments that include such select V2R antagonists for utility in treating clear cell renal cell carcinoma.